Seeking Alpha

Merck & Co Inc. (MRK)

  • Jan. 7, 2013, 3:02 PM
    Trius Therapeutics (TSRX +0.7%) says the FDA has designated it's Phase 3 antibiotic candidate, tedizolid phosphate, as a Qualified Infectious Disease Product for acute bacterial skin and skin structure infections, as well as for hospital-acquired/ventilator-associated bacterial pneumonia. The designation enables the company to benefit from certain incentives for the development of new antibiotics, including priority review and fast-track status.
    | Comment!
  • Jan. 7, 2013, 8:40 AM
    The FDA accepts Merck's (MRK) resubmission of a New Drug Application for its sugammadex sodium injection, which is used as a muscle relaxant during surgery. The FDA rejected the original NDA for sugammadex in 2008 and asked for additional information about allergic reactions and bleeding. (PR)
    | 1 Comment
  • Jan. 7, 2013, 7:41 AM
    Cubist Pharmaceuticals (CBST) reports Q4 revenue of $245.9M (+16% Y/Y) and FY12 revenue at $926.4M (+23% Y/Y). (PR)
    | Comment!
  • Jan. 2, 2013, 2:31 PM
    Mylan (MYL +0.5%) says the FDA has approved its Rizatriptan benzoate tablets - a generic version of Merck's (MRK) Maxalt tablets - for the treatment of migraine headaches in adults.
    | Comment!
  • Dec. 31, 2012, 9:00 AM
    Not all diagnostics companies are worried at the prospect of the Supreme Court striking down patents on two cancer-related genes "owned" by Myriad (MYGN) in a decision that is due to come in 2013. Quest (DGX) says it could be a "positive development," as it would "open new opportunities to develop new testing services." Myriad, which has spent 17 years and $500M on isolating the "DNA molecules and processes," isn't so sanguine.
    | Comment!
  • Dec. 20, 2012, 9:00 AM
    Merck's (MRK -2.9%) Tredaptive (Cordaptive) cholesterol treatment failed to meet its primary goal in a massive study of 25,673 patients. The drug didn't significantly cut the risk of coronary deaths, non-fatal heart attacks, strokes or revascularizations compared with statin therapy. Merck will end its bid to for regulatory approval of Tredaptive in the U.S.; the drug is sold in 40 countries and had sales of $13M in Q1-Q3. (PR)
    | 1 Comment
  • Dec. 18, 2012, 6:15 PM
    The top 10 dividend-yielding stocks from the "ultimate stock pickers" at Morningstar: GSK, COP, INTC, LLY, NVS, MRK, PM, PFE, SYY, JNJ.
  • Dec. 18, 2012, 8:39 AM
    Merck (MRK) signs a deal to use GE Healthcare's (GE) Flutemetamol imaging agent in clinical studies of Merck's MK-8931 drug for treating Alzheimer's disease. Flutemetamol, which performed well in its own Phase III trials, helps detect beta amyloid deposits in the brain. The build-up of beta amyloid has been associated with Alzheimer's. (PR)
    | Comment!
  • Dec. 13, 2012, 7:18 PM
    Merck (MRK) receives FDA approval to revise the biologics labeling on both the refrigerator-stable and frozen formulations of it's Chicken pox vaccine Varivax Details of the revised labeling aren't currently available.
    | Comment!
  • Dec. 13, 2012, 8:22 AM
    Merck (MRK) CEO Kenneth Frazier jostles for positioning in the fiscal cliff debate, warning that proposals to put "additional price controls on drugs" could "take away much of the incentive in the capital markets to invest in research and development." The Democrats have proposed reducing soaring medical costs by using Medicare to negotiate lower drug prices.
    | Comment!
  • Dec. 11, 2012, 6:48 PM
    Goldman Sachs (GS) gets the nod by Warburg Pincus to explore a sale of Bausch & Lomb, the company's eye-care division. Warburg is said to be seeking at least $10B for the business. According to reports, Goldman has already contacted Sanofi (SNY), GlaxoSmithKline (GSK), and Merck (MRK) this month, and that Abbott Laboratories (ABT) will be among the other companies contacted.
    | Comment!
  • Dec. 11, 2012, 10:48 AM
    Cardiome Pharma (CRME +41%) leaps higher out of an earlier trading halt after the company says it's reached a deal with Merck (MRK +0.6%) to settle its debt obligations stemming from it's collaboration on vernakalant - a treatment for atrial fibrillation - which it signed in April 2009. Under the terms of the settlement, CRME will pay MRK $20M to settle its outstanding debt of $50M, and MRK will terminate a $100M credit facility it had made available to CRME.
    | Comment!
  • Dec. 11, 2012, 8:53 AM
    India revokes yet another pharmaceutical patent owned by a foreign multinational, with Merck (MRK) losing protection for an asthma treatment after domestic drug-maker Cipla challenged an earlier decision. Pfizer, Roche and Novartis are among those to have experienced patent trouble in the country. (previous)
    | 1 Comment
  • Dec. 9, 2012, 2:27 AM
    The Supreme Court will review a "pay for delay" case in which Solvay, now owned by Abbott Labs (ABT), paid three generic drug companies to up to $40M a year, including Watson (WPI), to postpone making copycat versions of Solvay's Androgel testosterone treatment. The case has industry wide ramifications, with the FTC saying the practice costs customers $3.5B a year. (previous)
    | 1 Comment
  • Dec. 7, 2012, 4:41 AM
    The Supreme Court could say today whether it will review a case involving a "pay for delay" agreement in which a pharmaceutical company pays generic rivals tens of millions of dollars to hold off from launching copycat versions of medicines. The FTC says the practice costs customers $3.5B a year, while drug firms argue that it protects innovation. Companies that could be affected include Abbott (ABT), Watson (WPI), Merck (MRK), Bristol-Myers Squibb (BMY) and Teva (TEVA).
    | Comment!
  • Dec. 4, 2012, 8:13 AM
    An appeals court ruling yesterday that dismissed the conviction of a sales rep who sold a drug for non-FDA approved uses could have major ramifications for pharmaceutical companies, which have paid billions in fines for doing just that. Two out of three judges agreed with Alfred Caronia that his rights to free speech were violated. The government is expected to appeal the case, which could find its way to the Supreme Court.
Visit Seeking Alpha's
MRK vs. ETF Alternatives
Company Description
Merck & Co Inc is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products.